PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 1713872

A comparison between two different procedures for bone marrow processing: a semiautomated procedure vs manual starch sedimentation.

G Menichella·L Pierelli·R Serafini·M L Foddai·M Vittori·A Paoloni·M De Martini·P L Rossi·G Mango·B Bizzi
View original source ↗Export metadata ↓

Abstract

After high-dose chemotherapy, autologous cryopreserved bone marrow infusion is employed to restore rapidly the compromised hematopoietic function. An efficient bone marrow processing reduces the infusion toxicity produced by hemolized red cells, granulocytes and platelets clumping and DMSO amount; moreover it increases freezing efficacy, a critical step in autologous bone marrow grafting techniques. Gravity sedimentation technique with 6% hydroxyethyl-starch (HES) or a semiautomated procedure using a blood cell processor were used in our center to manipulate ex-vivo the collected bone marrow. In our experience we compared these two different procedure and we evaluated their efficiency.

Explore related subjects

Antineoplastic Combined Chemotherapy ProtocolsAutomationBlood SedimentationBone MarrowBone Marrow TransplantationCell SeparationCryopreservationHematopoietic Stem Cell TransplantationHumansHydroxyethyl Starch DerivativesLeukocytes, MononuclearPancytopeniaRadiotherapyTissue PreservationComparative StudyJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G Menichella, L Pierelli, R Serafini, M L Foddai, M Vittori, A Paoloni, M De Martini, P L Rossi, G Mango, B Bizzi. 1991. A comparison between two different procedures for bone marrow processing: a semiautomated procedure vs manual starch sedimentation.. https://pubmed.ncbi.nlm.nih.gov/1713872/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.

PURPOSE: The feasibility of adjuvant cisplatin, methotrexate and vinblastine chemotherapy was evaluated in Taiwanese patients with invasive transitional cell carcinoma at high risk for recurrence. MATERIALS AND METHODS: We assigned 56 patients with high risk transitional cell carcinoma (vascular or lymphatic invasion in the primary tumor, poorly differentiated stage P2, P3, P4 or N+ and M0) to receive adjuvant chemotherapy after radical urological surgery. The chemotherapy consisted of 40 mg./m.2 methotrexate and 4 mg./m.2 vinblastine on days 1 and 8, and 100 mg./m.2 cisplatin on day 2 given in 6 courses at 21-day intervals. RESULTS: Median followup was 44 months. An average of 4.63 cycles of chemotherapy was administered. The median actual survival was 44 months, and the 1 and 3-year survival probabilities were 92% and 50%, respectively. The median disease-free survival was 15.5 months, and the 1 and 3-year disease-free survival probabilities were 66% and 28%, respectively. Only 5 (9%) and 1 (2%) patients had grades 3 and 4 leukopenia, respectively, and none died of sepsis. CONCLUSIONS: The use of adjuvant cisplatin, methotrexate and vinblastine chemotherapy in patients with invasive transitional cell carcinoma at high risk for recurrence is feasible with tolerable toxicity but randomized controlled trials will be required to assess the benefit.

Antineoplastic Combined Chemotherapy Protocols↗